Qurient Co

Qurient Co Debt

The Debt of Qurient Co (115180.KQ) as of Nov 17, 2026 is 12.31 B KRW. In the previous year, Debt was 261.06 M KRW — a change of 4,614.96% (higher).

Debt

12.31 BKRW

YoY

4,614.96%

Last updated:

In 2025, Qurient Co's total debt was 12.31 B KRW, a 4,614.96% change from the 261.06 M KRW total debt recorded in the previous year.

The Qurient Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2014
50.52 B KRW
Jan 1, 2019
460.89 M KRW
Jan 1, 2020
755.83 M KRW
Jan 1, 2022
254.77 M KRW
Jan 1, 2023
35.50 M KRW
Jan 1, 2024
261.06 M KRW
Jan 1, 2025
12.31 B KRW
The Qurient Co Debt history
YEARDebtYoY
12.31 BKRW+4,614.96%
261.06 MKRW+635.47%
35.50 MKRW-86.07%
254.77 MKRW-66.29%
755.83 MKRW+63.99%
460.89 MKRW-99.09%
50.52 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Qurient Co's Debt Structure

Qurient Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Qurient Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Qurient Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Qurient Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Qurient Co stock

Debt of Qurient Co is 12.31 B KRW in 2025.

Debt of Qurient Co changed from 261.06 M KRW to 12.31 B KRW, representing a 4,614.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Qurient Co since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Qurient Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Qurient Co

All Key Metrics — Qurient Co